#7 - 22ndCentury Group (ASE:XXII)
22ndCentury Group (NYSEAMERICAN: XXII) - One of the cautionary tales about cannabis investing comes in the possibility that as the industry matures, other companies will bring their expertise to bear and overtake the category. 22ndCentury Group may be an example of that. This is a company that’s known for growing low-nicotine tobacco plants and that looks to finally be ready to contribute to the company’s bottom line. So with more revenue on the horizon, where might the company be looking to grow? Cannabis plants. The company currently controls several cannabis plant-related patents and has been working on a no-THC cannabis plant. THC is the component of cannabis that gets you high. The company is also conducting research that could lead to genetically engineered cannabis plants. This would allow the production of a product with optimized levels of cannabidiol (CBD) and other cannabinoids. While the work on both products is still in its infancy, it’s logical to think that this is the space that 22ndCentury Group will seek out.
About
- Current Price
- 0.00
- Consensus Rating
- N/A
- Ratings Breakdown
- 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- N/A